医学
放射性核素治疗
神经内分泌肿瘤
核医学
生长抑素受体
肽受体
PET-CT
多塔
实体瘤疗效评价标准
荟萃分析
置信区间
正电子发射断层摄影术
生长抑素
内科学
放射科
临床试验
临床研究阶段
受体
螯合作用
化学
有机化学
作者
Osher Ngo Yung Lee,Kel Vin Tan,Vrijesh Tripathi,Hui Yuan,WC Chan,K.W. Chiu
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2022-04-29
卷期号:47 (9): 781-793
被引量:6
标识
DOI:10.1097/rlu.0000000000004235
摘要
Purpose The aim of this study was to identify and evaluate the role of 68 Ga-DOTA–somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on the ability of PET/CT to impact clinical management and predict peptide receptor radionuclide therapy (PRRT) response. Patients and Methods A systematic literature search of articles up to December 2021 was performed using PubMed and Scopus. Eligible studies included ≥10 patients with confirmed or suspected NETs who had undergone pretreatment staging 68 Ga-DOTA-SSA PET/CT. A meta-analysis using the random-effects model was conducted to determine the overall change in management after PET/CT, whereas PET/CT-derived parameters that correlated with PRRT outcome were summarized from studies that assessed its predictive capabilities. Results A total of 39 studies were included in this systemic review, of which 2266 patients from 24 studies were included for meta-analysis. We showed that PET/CT resulted in a change in clinical management in 36% (95% confidence interval, 31%–41%; range, 3%–66%) of patients. Fifteen studies consisting of 618 patients examined the prognostic ability of 68 Ga-DOTA-SSA PET/CT for PRRT. Of those, 8 studies identified a higher pretreatment SUV to favor PRRT, and 4 identified PET-based radiomic features for somatostatin receptor heterogeneity to be predictive of PRRT response. Conclusions Along with its diagnostic abilities, 68 Ga-DOTA-SSA PET/CT can impact treatment decision-making and may predict PRRT response in patients with NETs. More robust studies should be conducted to better elucidate the prognostic role of somatostatin receptor PET/CT in optimizing treatment for clinical outcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI